InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
InnoCan Pharma Corporation (INNPF) - Total Liabilities
Latest total liabilities as of September 2025: $4.49 Million USD
Based on the latest financial reports, InnoCan Pharma Corporation (INNPF) has total liabilities worth $4.49 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InnoCan Pharma Corporation - Total Liabilities Trend (2015–2024)
This chart illustrates how InnoCan Pharma Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InnoCan Pharma Corporation Competitors by Total Liabilities
The table below lists competitors of InnoCan Pharma Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FLEXTRONICS INTL - Dusseldorf Stock Exchang
DU:FXI
|
Germany | €13.58 Billion |
|
Kmc Properties ASA
OL:KMCP
|
Norway | Nkr8.00 Million |
|
ON SEMICONDUCTOR
MU:XS4
|
Germany | €5.32 Billion |
|
TYSON FOODS -A- - Dusseldorf Stock Exchang
DU:TF7A
|
Germany | €19.53 Billion |
|
Sentoria Group Bhd
KLSE:5213
|
Malaysia | RM452.47 Million |
|
Ralco Agencies Ltd
TA:RLCO
|
Israel | ILA97.83 Million |
|
Panacea Life Sciences Holdings Inc
OTCQB:PLSH
|
USA | $234.03K |
Liability Composition Analysis (2015–2024)
This chart breaks down InnoCan Pharma Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InnoCan Pharma Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InnoCan Pharma Corporation (2015–2024)
The table below shows the annual total liabilities of InnoCan Pharma Corporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.24 Million | -12.37% |
| 2023-12-31 | $2.55 Million | +240.08% |
| 2022-12-31 | $751.00K | -78.93% |
| 2021-12-31 | $3.56 Million | -55.12% |
| 2020-12-31 | $7.94 Million | +579.30% |
| 2019-12-31 | $1.17 Million | +119.32% |
| 2018-12-31 | $533.00K | +38.42% |
| 2017-12-31 | $385.06K | +123.06% |
| 2016-12-31 | $172.63K | +95.15% |
| 2015-12-31 | $88.46K | -- |